NCT
HOME CURRENT ARCHIVE COVID-19
HOME CURRENT ARCHIVE PUBLISH INSTRUCTIONS
FOR AUTHORS COVID-19 LOG IN / REGISTER HISTORY ABOUT US DIRECTORY CONTACT
Pulmonary embolism, a multidisciplinary focusing

Marco Antonio Alcocer Gamba , Francisco González Juárez , Salvador León González , Eliodoro Castro Montes , Mario Alejandro Romero Osio , Luis Martín Loarca Piña , Ramón Félix Carpio Macías , José Antonio Martínez Reséndiz , Ramón Silos García





2006, Number 2

2006; 65 (2)






ABSTRACT

Pulmonary embolism (PE) it’s a pathological state secondary to thrombus formation in venous system, which migrate and embolized to pulmonary branches; depending on patient age, pulmonary localization and size of thrombus, time of evolution; and acute problems like trauma or adverse clinical conditions; all of them are principals index of morbidity and mortality which will have patients with PE event; this illness is one of the three principal causes of cardiovascular dead in our population, in fact it’s very important to have a multidisciplinary boarding, even to opportune diagnosis based on clinical principles, to identify differential diagnosis including hematological evaluation looking for prothrombotic statements, identifying risk factors as much as transitorily like permanent conditions, utility of non invasive studies like transthoracic echocardiogram and it’s different modalities, seric markers, which could bring us therapeutic strategies with best prognostic purposes as a individualized way, taking care to exclusively medical treatment, indication of different thrombolytic strategies, customary and alternative doses, use of interventional technology as vena cava temporal or permanent filters, thrombus fragmentation and extraction devices and surgical techniques like pulmonary endarterectomy; looking also to chronic ambulatory management and cardiopulmonary rehabilitation concepts.

KEYWORDS

Thrombolytic, multidisciplinary management, pulmonary endarterectomy, vena cava filters, pulmonary embolism.

REFERENCES

  1. Goldhaber SZ. Harrison Principles of internal medice 16th edition Denniss L. Casper El Al 2005 Chapter 244.

  2. Banfier A, Burghuber O, Herold Ch, Minar E, Watzke H. Clinical Respiratory Medice. Richard K, Albert Stephen G: Spiro, James R. Jett Second Edition. 2004 Mosby Chapter53.

  3. Jefrey W. Olin The Cleveland clinic intensive review of internal medicine. Second Edition. 2000 James K. Stoller Muzaffar Ahmad, David L. Longwrth chapter 36.

  4. Karwinski B, Svendsen E. Comparison of clinical and post mortem diagnosis of pulmonary embolism. J Clin Pathol 1989; 42: 135-9.

  5. Wells PS, Ginsberg JS, Anderson DR, et al. Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med 1998; 129: 997-1005.

  6. Wicki J, Perneger TV, Junod AF, et al. Assessing clinical probability of pulmonary embolism in the emergency ward: a simple score. Arch Intern Med 2001; 161: 92-7.

  7. Sadosty A, Boie E, Otead L. Pulmonary embolism. Emerg Med Clin N Am 2003; 21: 363-384.

  8. Riedel M. Diagnosing pulmonary embolism. Postgrad Med J 2004; 80: 309-319.

  9. Girad P, Musset D, Parent F, Maitre S, Philippoteau C, Smonneau G. High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism. Chest 1999; 116: 903-8.

  10. Heit JA. The epidemiology of venous trhomboembolism in the community: implications for prevention and management. J Throm Thrombolysis 2006; 21(1): 23-29.

  11. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JC. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998; 279: 458-62.

  12. Samana MM, Dahl OE, Quinlan DJ, Mismetti P, Rosencher N. Quantification of risk factors the development of a risk assessment tool. Haematologica 2003; 88: 1410-21.

  13. Stein P, Alavi A, Gottschalk A, et al. Usefulness of non invasive diagnostic tools for diagnosis of acute pulmonary embolism in patients with a normal chest radiograph. Am J Cardiol 1991; 67: 1117.

  14. Hansson PO, Welin L, Tibblin G, Ericsson H. Deep vein thrombosis and pulmonary embolism in the general populations. “The Study of Men Born in 1913”. Arch Intern Med 1997; 157: 1665.

  15. Wells PS, Anderson DR, Rodger M, et al. Derivation of simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 2000; 83: 416-20.

  16. Wicki J, Perneger TV, Junod AF, Bounameaux H, Perrier A. Assessing clinical probability of pulmonary embolism in the emergency ward: a simple score. Arch Intern Med 2001; 161: 92-6.

  17. Bosson JL, Labarere J. Determining indications for care common to competing guidelines by using classification tree analysis: Application to the prevention of venoues Thromboembolism in medical inpatients. Medical Decision Making 2006; Jan-Feb 2006: 63-75.

  18. Geerst WH, Pineo GF, Heit JA, Bergquist D, Lassen MR, Colwell CW, Ray JG. Prevention of Vemous Thromboembolism. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:338(S)-400(S).

  19. Jerjes-Sánchez C, Sandoval Zárate J, Gutiérrez-Fajardo P, et al. Diagnóstico, estratificación y tratamiento de la tromboembolia pulmonar aguda. Guías y Recomendaciones del Capítulo de Circulación Pulmonar de la Sociedad Mexicana de Cardiología. Archivos de Cardiología de México 2004; l74(Supl. 3): S547-S585.

  20. Kasper W, Konstantinides S, et al. Management Strategies and Determinants of Outcome in Acute Major Pulmonary Embolism: Results of a Multicer Registry. J Am Coll Cardiol 1997; 30: 1165-71.

  21. Golhaber SZ, Visan L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353: 1386-9.

  22. Wong SP, Otto CM. Echocardiographic Findings in Acute and Chronic Pulmonary Disease in The Practice of Clinical Echocardiography. 2nd Ed. Saunders, 2002: 754-755.

  23. McConnell MV, Salomon SD, Rayan ME, et al. Regional right ventricular dysfunction detected by echocardiography in acute pulmonary embolism. Am J Cardiol. 1996; 78: 469-73.

  24. Goldhaber S. Echocardiography in the Management of Pulmonary Embolism. Ann intern Med. 2002; 136: 691-700.

  25. Kucher N, Luder C, Dörnhöfer T, et al. Novel Management strategy for patients with suspected pulmonary embolism. European Heart Journal 2003; 24: 366-376.

  26. Pruszczyk P, Torbicki A, Kuch-Wocial A, et al. Diagnostic value of transoesophageal echocardiography in suspected haemodynamically significant pulmonary embolism. Heart 2001; 85: 628-634.

  27. Meyer T, Binder L, Hruska N, Luthe H, Buchwald AB. Cardiac Troponin I Elevation in Acute Pulmonary Embolism Is Associated With Right Ventricular Dysfunction. J Am Coll Cardiol 2000; 36: 1632-6.

  28. Binder L, Pieske B, Olschewski M, Geibel A, et al. NTerminal Pro-Brain Natriuretic Peptide or Troponin Testing Followed by Echocardiography for Risk Stratification of Acute Pulmonary Embolism. Circulation 2005; 112: 1573-1579.

  29. Giannitsis E, Katus HA. Editorial, Risk Stratification in Pulmonary Embolism Based on Biomarkers and Echocardiography. Circulation 2005; 112: 1520-1521.

  30. Scridon T, Scridon C, Skali H, et al. Prognostic Significance of Troponin Elevation and Right Ventricular Enlargement in Acute Pulmonary Embolism. Am J Cardiol 2005; 96: 303-306.

  31. Labardini MJR. Padecimientos Mieloproliferativos Crónicos y Mielofibrosis, México, J Guillermo Ruíz-Argüelles, 2003: 261-278.

  32. Schafer AI. Thrombocytosis. NEJM 2004; 350(12): 1211-1219.

  33. Seligsohn U, Lubetsky A. Genetic Susceptibility to Venous Thrombosis. NEJM 2001; 344(16):1222-1231.

  34. Levine JS, Branch W, Rauch J. The Antiphospholipid Syndrome. NEJM 2002; 346(10): 752-763.

  35. Farber HW, Loscalzo J. Pulmonary Arterial Hypertension. NEJM 2004; 351(16): 1655-1665.

  36. Tefferi A. Myelofibrosis with Myeloiide Metaplasia. NEJM 2000; 342(17): 1255-1265.

  37. Collins R, Scrimgeour A, Yusuf S, et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials general, orthopedic, and urologic surgery. N Engl Y Med 1988; 318: 1161-73.

  38. Goldhaber SZ, Haire WP, Feldstein ML, Millar M, Toltzis R, Smith JL, Alteplase versus heparin in acute pulmonary embolism, randomized trial assessing rigth ventricular function and pulmonary perfusion. Lancet 1993: 341.

  39. Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolisis compared with heparin for the initial treatment of pulmonary embolism. Circulation 2004; 110: 744-749.

  40. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002; 347: 1143.

  41. Rogers LQ, Lutcher CL. Streptokinase therapy for deep venous thrombosis: a comprehensive review of the literature. Am J Med 1990; 88: 389.

  42. Konstantinides S, Geibel A, Olsschewski M, et al. Importance of cardiac troponin I and T in risk stratification of patients with acute pulmonary embolism. Circulation 2002; 106: 1263-1268.

  43. Schellong SM, Schmidt BA. New therapeutic approaches in pulmonary embolism. Respiration 2003; 70: 559-568.

  44. Daniel LB, Parker JA, Patel SR, Grodstein F, Goldhaber SZ. Relation of duration of symptoms with response to thrombolitic therapy in pulmonary embolism. Am J Cardiol 1997: 80, 184-188.

  45. Kelley MA, Abdul S. Massive pulmonary embolism. Clin Chest Med 1994; 15: 547-560.

  46. Moser KM. Venous Thromboembolism. Am Rev Respir Dis 1990; 141: 235-249.

  47. Ruiz M, Ramos JA, Aguayo E. Thrombolysis during cardiopulmonary resuscitation in fulminant pulmonary embolism: A review. Crit Care Med 2001; 29(11): 2211-2219.

  48. Buller HR, Davidson BL, Decousus H, et al. MATISSE investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140: 867-873.

  49. Motsch J, Walther A, Bock M, Bottiger D. Update in the prevention and treatment of deep venous thrombosis and pulmonary embolism. Curr Opin Anestesiol 2006; 19: 52-58.

  50. Tebbe U, Graf A, Kanke W, et al. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. Am Heart J 1999; 138: 39-44.

  51. Zavaleta MEO, Morales BJE. Tromboembolia Pulmonar. Neumología y Cirugía de Tórax 2006; 65(1): 24-39.

  52. Ginsberg JS. Management of Venous Thromboembolism. N Engl J Med. 1996; 335(24):1816-28.

  53. Tail RC. Anticoagulation in patients with thromboembolic disease. Thorax 2001; 56(Suppl II): ii30-ii37.

  54. Liu P, Meneveau N, Schiele F, Bassand JP. Long-term outcome of acute massive pulmonary thromboembolism following thrombolysis. Zhonghua Nei Ke Za Zhi 2002; 41(11): 750-3.

  55. Sharma S, Kashour T, Philipp R. Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade. Tex Heart Inst J 2005; 32(3): 405.

  56. Hoeper M, Kramm T, Wikens H, et al. Bosentan Therapy for Inhoperable Chronic Thromboembolic Pulmonary Hypertension. Chest 2005; 128(4): 2363-7.

  57. Pengo V, Lensing A, Prins M, et al. Incidence of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism. N Engl J Med 2004; 350: 2257-64.

  58. Fedullo P, Auger W, Kerr M, et al. Chronic Thromboembolic Pulmonary Hypertension. Engl J Med 2001; 345: 1465-72.

  59. Lewczuk J, Piszko P, Jagas J, et al. Prognostic Factors in Medically Treated Patients With Chronic Pulmonary Embolism. Chest 2001; 119: 818-823.

  60. Rubin LJ. Pulmonary Herat Disease. Baum´s Textbook of pulmonary Diseases. Philadelphia. Lippincott ´Williams & Wilkins. 2004.

  61. Bonderman D, Nowotny R, Skoro-Sajer N, et al. Bosentan Therapy for Inoperable Chronic Thromboembolic Pulmonary hypertension. Chest 2005; 128(4): 2599-603.

  62. Hughes R, George P, Parameshwar J, et al. Bosentan in inoperable chronic thromboembolic pulmonary hypertension. Thorax. 2005; 60(8): 707.

  63. Ghofrani HA, et al. Sildenafil for Long Term Treatment of nonoperable Chronic Thromboembolic Pulmonary Hypertension. Am J Respir Crit Care Med 2003; 167(8): 1139-41.

  64. Ono F, Nagaya N, Okumura H, et al. Effect of Orally Active Prostacyclin Analogue on Survival in Patients With Chronic Thromboembolic Pulmonary Hypertension Without Major Vessel Obstruction. Chest 2003; 123: 1583-1588.

  65. Sánchez-Lafuente G. La prueba de esfuerzo neumológica. Prueba de esfuerzo Cardiaca, Respiratoria y Deportiva. Edika Med. Barcelona. 2002: 73-90.

  66. Pulmonary Rehabilitation-1999. This Official Statement of The American Thoracic Society was Adopted by The ATS Board of Directors, November. Am J Respir Crit Care Med 1999; 159: 1666-1682.

  67. Uchi M, Saji T, Harada T. Feasibility of cardiopulmonary rehabilitation in patient with idiopathic pulmonary arterial hypertension treated with intravenous prostacyclin infusion therapy. J Cardiol 2005; 46(5): 183-93.

  68. Sing RF, Rogers FB, Novitsky YW, Heniford BT. Optional Vena Cava Filters for Patients with High Thromboembolic Risk: Questions to be Answered. Surgical Innovation 2005; 12(3): 195-202.

  69. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Massive Pulmonary Embolism. Circulation 2006; 113: 577-582.

  70. Chiou AC, Biggs KL, Matsumura JS. Vena Cava Filters: Why, When, What, How? Pers Vasc Surg Endovasc Ther 2005; 17(4): 329-339.

  71. Grassi CJ, Swan TL, Cardella JF, et al. Quality Improvement Guidelines for Percutaneous Permanent Inferior Vena cava Filter Placement for the Prevention of Pulmonary Embolism. J Vasc Interv Radiol 2001; 12: 137-141.

  72. Augustinos P, Ouriel K. Invasive Approaches to Treatment of Venous Thromboembolism. Circulation 2004; 110(Suppl I): I27-I34.

  73. Goldhaber SZ, Elliot G. Acutte Pulmonary Embolism: Part II Risk Stratification, Treatment, and Prevention. Circulation 2003; 108: 2834-2838.

  74. Ascher E, Hingorani A, Tsemekhin B, et al. Lessons learned from a 6 years clinical experience with superior vena cava Greenfield filters. J Vasc Surg 2000; 32: 881-887.

  75. Aburahma AF, Mullins DA. Endovascular caval interruption in pregnant patients with deep vein thrombosis of the lower extremity. J Vasc Surg 2001; 33: 375-378.

  76. Greenfield LJ, Cho KJ, Äis SO, et al. Preliminary clinical experience with the titanium Greenfield vena caval filter. Arch Surg 1989; 124: 657-659.

  77. Streiff MB. Vena caval filters: a compressive review. Blood 2000; 95: 3669-3677.

  78. Schutzer R, Ascher E, Hingorani A, et al. Preliminary results of the new 6F TrapEase inferior vena cava filter. Ann Vasc Surg 1989; 17: 103-106.

  79. Grande WJ, Trerotola SO, Reilly PM, et al. Experience with the Recovery Filter as a Retrieval Inferior Vena Cava Filter. J Vasc Interv Radiol 2005; 16: 1189-1193.

  80. Morris ChS, Rogers FB, Najarian KE, et al. Current Trends in Vena Caval Filtration with the Introduction of a Retrievable Filter at Level I Trauma Center. J Trauma 2004; 57: 32-36.

  81. Stone PA, Aburahma AF, Hass SM, et al. TrapEase inferior vena cava filter placement: use of the subclavian vein. Vasc Endovasc Surg 2004; 38: 505-508.

  82. Rosenthal D, Wellons ED, Levitt AB, et al. Role of Prophylactic Temporary Inferior Vena Cava Filters placed at the ICU bedside under intravascular ultrasound guidance in patients with multiple trauma. J Vasc Surg 2004; 40: 958-964.

  83. Millward SF, Oliva VL, Bell SD, et al. Günter Tulip Retrieval Vena Cava Filter: Results from the Registry of the Canadian Interventional Radiology Association. J Vasc Interv Radiol 2001; 12: 1053-1058.

  84. Binkert CA, Bansal A, Gates JD. Inferior Vena Filter after 317-day Implantation. J Vasc Interv Radiol 2005; 16: 395-398.

  85. Allen TL, Carter JL, Morris BJ, et al. Retrievable vena cava filters in trauma patients for high risk prophylaxis and prevention of pulmonary embolism. The Am J of Surgery 2005; 189: 656-661.

  86. Blebea J, Wilson R, Waybill P, et al. Deep venous thrombosis after percutaneous insertion of vena caval filters. J Vasc Surg 1999; 30: 821-829.

  87. Poletti PA, Becker CD, Prina L, et al. Long-term results of the Simon Nitinol inferior vena cava filter. Eur Radiol 1998; 8: 289-294.

  88. Willward SF, Peterson RA, Moher D, et al. LGM (Vena Tech) vena caval filter: experience at a single institution. J Vasc Interv Radiol 1994; 5: 351-356.

  89. Uflacker R. Interventional Therapy for Pulmonary Embolism. J Vasc Interv Radiol 2001; 12: 147-164.

  90. Jamieson SW, Kapelanski DP, Sakakibara N, et al. Pulmonary Enarderectomy: Experience and Lessons Learned in 1,500 Cases. Ann Thorac Surg 2003; 76: 1457-64.

  91. Sandoval J, Gómez A, Palomar A, et al. Hipertensión arterial pulmonar crónica secundaria a tromboembolia pulmonar no resuelta. Caracterización clínica, hemodinámica y sobrevida. Neumología y Cirugía de Tórax 2003; 62(2): 83-91.

  92. Sáenz C, Sánchez S, Velázquez M, et al. Guías de práctica clínica de la Sociedad Española de Cardiología en tromboembolismo e hipertensión pulmonar. Rev Esp Cardiol 2001; 54: 194-210.

  93. Daily PO, Johnston GG, Simmons CJ, Moser KM. Surgical management of chronic pulmonary embolism. J Thorac Cardiovasc Surg 1980; 79: 523-531.

  94. Masuda M, Nakajima N. Our Experience of Surgical Treatment for Chronic Pulmonary Thromboembolism. Ann Thorac Cardiovasc Surg 2001; 7(5):261-5.

  95. British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. British Thoracic Society Standards of Care Committee Pulmonary Embolism Guideline Development Group. Thorax 2003; 58; 470-483.

  96. Kucher N, Goldhaber SZ. Management of Massive Pulmonary Embolism. Circulation 2005; 112: e28-e32.


2006, Number 2

2006; 65 (2)